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Abstract 
Background: Chronic hand eczema (CHE) is a chronic dermatological condition that 
entails skin dryness, blistering and pruritus, and reduces the quality of life. 0.5 to 0.7% 
of the general population suffer from a severe form of this disease which leads to 
seriously impaired quality of life, manual dexterity, work absenteeism, and prevents 
employment. (1, 2) There are several treatment options for CHE, pharmaceutical and 
others, but they are unlicensed for treatment of eczema . There is a new drug, 
alitretinoin  (Toctino®), that is a licensed medication for severe CHE. It is expensive, 
however, the evidence of effectiveness has been disputed. The Norwegian Medicines 
Agency denied alitretinoin reimbursement due to lack of clinical data on effectiveness. 
 
Aim: To estimate the additional costs and additional health benefits of replacing 
azathioprine by alitretinoin in the treatment of severe CHE. 
 
Methods: A systematic literature review was conducted to estimate the clinical 
effectiveness of competing treatments for severe CHE, among which alitretinoin and 
azathioprine were the only relevant treatments. A decision tree was developed to 
compare the cost-effectiveness of two different doses of alitretinoin versus 
azathioprine. The estimated time horizon of the model was 1 year. The incremental cost 
per QALY was calculated and two types of sensitivity analyses were performed. 
 
Results: The model indicated that a one-year expected QALY was 0.681 with 
azathioprine, 0.701 for alitretinoin 30 mg and 0.695 for alitretinoin 10 mg, while the 
expected costs were NOK6061 for azathioprine, NOK37,297 for alitretinoin 30 mg, and 
NOK40,339 for alitretinoin 10 mg, respectively. While alitretinoin 10 mg is dominated 
(higher costs and lower effectiveness), the incremental cost of replacing azathioprine 
with alitretinoin 30 mg was NOK1.562 million per QALY. One-way sensitivity analyses 
indicate that the quality-of-life (QoL) parameters were the most important in terms of 
uncertainty. The probabilistic sensitivity analysis showed that the probability that 
alitretinoin 30 mg would be cost-effective is less than 24%. 
 
  VI 
Conclusion: Replacing azathioprine by alitretinoin is not cost-effective by conventional 
cost-effectiveness threshold. 
 
  VII 
Abbreviations 
 
AE/AD Atopic Eczema/Atopic Dermatitis 
CE Cost-Effectiveness 
CEA Cost-Effectiveness Analysis 
CHE Chronic Hand Eczema 
DLQI Dermatology Life Quality Index 
EASI Eczema Area and Severity Index 
HECSI Hand Eczema Severity Index 
HRQoL Health-Related Quality of Life 
PGA Physicians’ Global Assessment 
POEM Patient-Oriented Eczema Measure 
PSA Probabilistic Sensitivity Analysis 
RCT Randomized Controlled Trial 
SASSAD Six Area, Six Sign Atopic Dermatitis Severity Score 
SCORAD Severity Scoring of Atopic Dermatitis Index 
SF-36 Short Form-36 
QALY Quality-Adjusted Life Year 
QoL Quality of Life 
WTP Willingness-to-Pay 
 
  VIII
Contents 
Foreword…………………………………………………………………………………………………….......III 
Acknowledgement…………………………………………………………………………………………...IV 
Abstract………………..…………………………………………………………………..……………………...VI 
Abbreviations………………………………………………………………………………………………..VIII 
Contents…………………………………………………………………………………………..……………….IX 
 
1. Introduction 
1.1 Hand eczema…………………………………………………………………………………….1 
1.2 Measures of effectiveness in dermatology………………………………………….6 
1.3 Effectiveness of the therapies…………………………………………………………..13 
 
2. Methods 
2.1 Literature search……………………………………………………………………………..18 
2.2 Model……………………………………………………………………………………………...19 
2.2.1 Dosage………………………………………………………………………………….….22 
2.2.2 Costs………………………………………………………………………………………..22  
2.2.3 Probabilities…………………………………………………………………………….24  
2.2.4 Health Related Quality of Life……………………………………………………25  
2.2.5 Cost-effectiveness threshold……………………………………………………..26 
 
3. Results………………………………………………………………………………………………………..27 
   
4. Discussion 
 4.1 Strengths and limitations……………………………………………………………….. .31 
 4.2 Comparison with other studies………………………………………………………..33 
4.3 Implications…………………………………………………………………………………....34 
 
5. Conclusion………………………………………………………………………………………………35  
 
Reference list …………………………………………………………………………………………….36 
Appendix……………………………………………………………………………………….……..…….39 
 
 
  
 
 1 
Introduction 
1. Hand eczema 
Hand eczema is a common non-contagious dermatological condition, also called 
dermatitis, and manifests itself in inflammation of the upper layers of the skin.  Clinical 
signs of eczema are erythema, scaling, edema, vesicles, papules, often oozing, fissures, 
hyperkeratosis, pruritus and pain. (1, 3, 4) Eczema is a general term for a skin condition 
that can be classified into several subtypes.  
Aetiology (type of hand eczema) 
Exogeneous 
-     Irritant HE (ICD10 L24: Toxic contact dermatitis)  
- Allergic HE (ICD10 L23: Allergic contact dermatitis)  
Endogeneous 
- Atopic HE (ICD10 L20: Atopic dermatitis)  
- Other endogeneous HE (ICD10 L30: Other dermatitis) 
Localization 
- Dorsum of the hands 
- Palmar 
- Sides of the fingers 
- Finger tips 
- Finger webs 
- Wrist 
Morphology 
- Vesicular (pompholyx type) 
- Erythematoaquamous, scaling, fissures 
- Hyperkeratotic – rhagadiform/tylotic 
Discoid (nummular patches) (1) 
 
Etiologic classification includes irritant contact dermatitis, allergic contact dermatitis, 
atopic hand dermatitis, hybrid hand eczema (the combination of the three types 
mentioned above), and protein contact dermatitis. (3) Irritant contact dermatitis is 
associated with repeated use of irritants (mild toxic agents) that lead to an 
inflammation of the skin. Exposure to water and soaps and other detergents (the so 
called “wet work”) may provoke the development of hand eczema. This is the most 
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frequent external cause of hand eczema. Allergic contact dermatitis is provoked by 
exposure to contact allergens, such as nickel (in tools or jewellery), chromate (in leather 
or cement), rubber additives (in gloves) and preservatives (in creams and cosmetics). 
(3) Atopic hand dermatitis often happens in individuals with a history of asthma, hay 
fever or “childhood eczema”.  Atopy is an endogeneous factor of eczema development. 
Protein contact dermatitis frequently occurs in patients who are occupied in food 
industry. (3) Unfortunately, hand eczema does not always fall under a certain subtype 
description and is not caused by a specific factor. In many cases this condition is 
multifactorial, especially in patients with chronic hand eczema. 
No currently existing classification of eczema excludes hybrids and combinations 
of the various morphological categories. It especially refers to a chronic form of the 
disease, when the aetiological factor is not easily identified. It often has a remitting and 
relapsing character, but unfortunately this condition is incurable (it mostly refers to 
atopic and other endogeneous types of eczema or exogeneous types, when the causative 
factor cannot be avoided or eliminated).  
Occupation-related hand eczema takes the first rank of all occupational diseases 
in many countries. (1) According to Scandinavian studies, the incidence of hand eczema 
ranges from 5.53 to 8.8 per 1000 person-years. (5) A 2006 survey in Denmark reported 
a prevalence of 14%. (5) Population- and occupation-based studies conducted in 
Sweden found that the 1-year prevalence of chronic hand eczema was in the range of 
7% to 12%, with a higher prevalence among female patients and those aged 20 to 39 
years.(6) Atopic dermatitis, only one form of hand eczema, is one of the most common 
dermatological conditions affecting 15 mln people in the United States. (4) 
As reported, the point prevalence of hand eczema is 4% [95% CI] among adults 
in the general population, and a 1-year prevalence of up to 10% [95% CI], depending on 
whether the disease definition includes mild cases, and lifetime prevalence of 15%. 
[95%] (3, 7) The results are summarized from population-based studies performed 
during 1964 - 2007 time period; 30 out of 36 studies were from Sweden, Denmark, 
Norway and Finland. (7) The incidence of work-related cases (which are usually more 
severe than cases in the general population) that are reported to occupational health 
authorities is between 0.7 and 1.5 cases per 1000 workers per year . (3) There are 
certain occupations that suffer from hand eczema more frequently than others. These 
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are healthcare professionals, including nurses and cleaners, veterinarians, 
metalworkers, cement workers, hairdressers, gardeners  and farmers. (1) 
When it comes to differential diagnosis, it is important to differentiate hand 
eczema from other dermatological conditions it may be confused with. There are 
several skin diseases that mimic its symptoms and signs. Most frequently hand eczema 
is confused with psoriasis, mycosis (fungal infection), pustulosis palmoplantaris, herpes 
simplex, latex allergy and self-induced lesions. (3) 
Correct diagnosis of eczema leads to better management of the disease. 
Diagnosis of hand eczema usually consists of collecting medical history of previous 
episodes of hand eczema and atopy; examining the localization (palmar, dorsal, wrist, 
involvement of the feet etc.) and morphology of the lesions (dry scaly skin, 
hyperkeratosis, fissures, vesicles etc.); duration of remissons and relapses of the 
diseases, and possible exposure to any irritants and allergens. (1) 
In order to exclude contact allergy to external agents patch tests should be 
conducted on patients. In case of protein contact dermatitis, determining the level of IgE 
in blood serum may be of value. But as was mentioned above, hand eczema is often 
triggered by several factors and distinguishing the cause of the disease on examination 
may be impossible.  
Apart from immediate pharmacotherapy, treatment of hand eczema includes 
preventive measures. It is routinely recommended to all patients with hand eczema to 
use emollients and ointments as an adequate skin protection measure. Specifically, 
since many patients with eczema are prone to allergies and responsive to irritants, 
ointments should be hypoallergenic and should not contain any preservatives. 
Protective measures are especially important to those suffering from occupational 
eczema since they are exposed to potential risk factors. It is argued that the role of 
protective gloves is controversial, because gloves in themselves can lead to allergic 
contact dermatitis, but they offer protection to those patients doing the “wet work”. An 
experimental study showed that cotton lining or inner glove is recommended to 
individuals wearing protective gloves. (3) 
There is a general recommendation to eczema patients to reconsider their 
lifestyle; education is required. (1) 
When it comes to therapy, there are two escalating steps of treatment: topical 
treatments and systemic treatments. (1) Most common topical treatments include 
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topical corticosteroids, topical immunomodulators, irradiation with ultraviolet rays 
(UVA/UVB) or X-rays. Systemic treatments include oral pharmaceuticals: azathioprine, 
cyclosporine (and other immunosuppressants), retinoids and corticosteroids. (1) 
Topical corticosteroids are the first-line therapy for hand eczema. (3) They are 
efficient in the short-term, but their efficiency and safety in the long run are unknown. 
(5) Topical tacrolimus and pimecrolimus are calcineurin inhibitors (an 
immunosuppressant) are prescribed if topical glucocorticosteroids either failed or were 
not well tolerated or were inappropriate, but they are slightly more or equally efficient 
in treating hand eczema. (3, 5) The next alternative is phototherapy. It is frequently 
used as second-line treatment for the patients who were refractory to topical therapy. 
(3) It includes irradiation with ultraviolet light: UVA alone, photochemotherapy with 
psoralen (oral or topical) and UVA, and UVB. 
Once hand eczema becomes chronic and irresponsive to topical treatments, 
systemic therapy may be identified. Oral retinoids are preferred to oral 
immunisuppressant agents first, due to their better safety. (3) But retinoids (including 
alitretinoin) also have a list of side effects associated with them, and they are used in 
case of severe chronic hand eczema only. Immunosuppressive therapy (cyclosporine, 
azathioprine, methotrexate, etc.) are also used in severe chronic hand eczema refractory 
to topical treatments, but has a potential risk of adverse events, hence the burden of 
disease should be weighted against these risks. (3) 
It is important to note that the above-mentioned guidelines for management of 
hand eczema refer to all forms of the disease, including mild cases. However, in the 
following part of the thesis I will concentrate only on the treatment of chronic hand 
eczema. Patients with severe chronic hand eczema make up 0.5 - 0.7% of the general 
population. (2) They experience psychological distress because of its visibility, apart 
from immediate skin discomfort, which adds to the burden of the disease. Some 
manifestations of hand eczema, like painful fissures, vesicles, susceptibility to secondary 
infections, limit manual dexterity and lead to unemployment. (2) It was shown in 
several studies that chronic hand eczema has been a major cause for work absenteeism 
and even job loss. (2, 6)  
There are several types of therapies used for treatment of hand eczema. The 
first-line therapy is topical steroids with potency that matches the disease severity. In 
case of chronic eczema refractory to steroidal treatment, topical immunomodulators 
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(tacrolimus/pimetacrolimus) may be used. When topical treatments have no impact on 
the disease, oral pharmaceutical therapy is used. Oral drug therapy includes retinoids 
(alitretinoin, acitretin) and immunosuppressants (cyclosporin, azathioprine, 
methotrexate). These treatment options are not used in mild cases of eczema. Another 
type of therapy is Grenz rays irradiation and photo(chemo)therapy (i.e. irradiation with 
UVA/UVB rays or a combination of psoralen with UVA irradiation – PUVA).  
Although the patient population suffering from severe CHE is small, the disease 
has a high impact on disability, and leads to an economic loss to both individuals and 
society. Therefore the main subject of this study is to evaluate the effectiveness and 
cost-effectiveness of alitretinoin (Toctino®) comparing to another treatment for severe 
chronic hand eczema. In practice there are many treatment options available, including 
cyclosporin, azathioprine, methotrexate, Grenz rays, UVA/UVB/PUVA irradiation, 
topical immunosuppressants (tacrolimus/pimecrolimus), acitretin, Chinese herbal 
therapy etc. The clinical data on these treatments are very limited, and for the purposes 
of this study I chose azathioprine as a comparator since it had the best documentation.  
Health-related quality of life (HRQoL) measurement is an important point in 
estimating the effectiveness of a treatment in hand eczema. In hand eczema it can be 
done with the help of generic utility instruments and dermatology-specific and disease-
specific instruments. The most commonly used generic utility instrument is SF -36. The 
dermatology-specific instruments for measuring QoL are DLQI and Skindex-29/17. 
These instruments allow measuring utilities, while eczema-specific instruments (EASI, 
SASSAD, SCORAD, HECSI, POEM, PGA, PBI, Photographic guide etc.) only measure the 
disease activity and disease severity, and cannot evaluate the HRQoL in eczema 
patients, but are widely used in assessing the effectiveness of different eczema 
treatments. More on the instruments description will come in the section about the 
HRQoL measurement.  
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2. Measures of effectiveness in dermatology 
Health-related quality of life (HRQoL) is an important measure of the severity of the 
disease based on the patients’ perception of its effects and the impact on the patients’ 
life. (8) HRQoL combines physical, psychological and social dimensions, which are 
particularly significant in dermatology. “In dermatology, QoL and its measurement hold 
a special meaning as many skin diseases are chronic and their burden is associated 
more in living with the disease than in dying from it. Moreover, the visible nature of 
many skin diseases is associated with significant psychosocial impact, something not 
directly measurable with traditional clinical outcome measures and which makes 
evaluation of QoL even more crucial in dermatology. It was for this reason that various 
dermatology-specific and disease-specific measures have been developed to quantify 
the impact of skin diseases on patients’ QoL.”(9) “In dermatology, HRQOL can be 
assessed with generic instruments (i.e., applicable in a broad range of conditions 
allowing for comparisons between diseases), dermatology-specific instruments (i.e., 
applicable in all skin diseases and allowing for comparisons between skin diseases) and 
disease-specific instruments (i.e., use is restricted to a specific skin disease and only 
comparisons between patient groups with the same skin condition are possible).” (10) 
The most commonly used generic instrument is SF-36; dermatology-specific – DLQI and 
Skindex-29/17. There are also several disease-specific scores developed, that are used 
for evaluation of disease severity and disease activity. These eczema-specific scores are 
EASI, HECSI, SASSAD, SCORAD, POEM, PGA, PBI, and photographic guide. A more 
detailed description of all the instruments is given below. 
 
EASI (Eczema Area and Severity Index) 
EASI is a scoring system used in the assessment of disease severity in atopic dermatitis. 
EASI was developed as an instrument of “accurate assessment of  the extent and severity 
of atopic dermatitis”. (11) PASI (psoriasis area and severity index) was used as a 
prototype for the eczema-specific scoring system as a standardized instrument. It 
consists of two components: body region involvement and disease severity, which can 
be used separately or in combination to yield a more complete assessment. (11) 
“It focuses on the key acute and chronic signs of inflammation (i.e. erythema, 
induration/papulation, excoriation, and lichenification). EASI excludes non-key signs 
such as xerosis and scaling, oozing and crusting, and subjective parameters such as 
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pruritus and sleep loss in order to focus the index on key disease signs and to avoid 
mixing objective parameters with subjective symptoms.” (11) EASI can be used in both 
pediatric and adult dermatology since it is adaptable for children. 
In the scope of this work, EASI cannot be considered as a universal disease-
specific score, because it concentrates only on atopic dermatitis as a form of eczema, 
and it is not limited to hands.  
 
HECSI (Hand Eczema Severity Index) 
HECSI is also a scoring system for assessing the extent and severity of the disease. The 
body area that it assesses is constrained by the hands and the scoring system does not 
specify which type of eczema it implies. “Each hand is divided into five areas [fingertips, 
fingers (except the tips), palms, back of hands and wrists]. For each of these areas the 
intensity of the six following clinical signs: erythema, induration⁄papulation, vesicles, 
fissuring, scaling and oedema was graded on the following scale: 0, no skin changes; 1, 
mild disease; 2, moderate and 3, severe. For each location (total of both hands) the 
affected area was given a score from 0 to 4 (0, 0%; 1, 1–25%; 2, 26–50%; 3, 51–75% 
and 4, 76–100%) for the extent of clinical symptoms. Finally, the score given fo r the 
extent at each location was multiplied by the total sum of the intensity of each clinical 
feature, and the total sum called the HECSI score was calculated, varying from 0 to a 
maximum severity score of 360 points.” (12) 
HECSI is an assessment instrument based on objective clinical signs, and it does 
not include subjective symptoms, such as pruritus, into their assessment, as well 
functional impairment and quality of life.(12) The assessment process is run by 
physicians, but patient-oriented questionnaires, where they can evaluate subjective 
parameters, should be used in combination with HECSI. These parameters are highly 
important for estimating the level of impairment, and therefore it is suggested to use 
with a HRQoL measure, such as DLQI. (12) 
 
SASSAD (Six Area, Six Sign Atopic Dermatitis Severity Score)  
SASSAD is another disease-specific scoring system for assessing the disease activity in 
atopic eczema by six objective signs of the eczema affecting six zones of the body.  “The 
score comprises assessment of six signs: erythema, exudation, excoriation, dryness, 
cracking and lichenification; at six sites: arms, hands, legs, feet, head and neck, trunk; 
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each on a scale of 0 (absent), 1 (mild), 2 (moderate), or 3 (severe). The total range is 
therefore 0-108.” (13, 14) 
The SASSAD is quite often used in assessing the severity and extent of the 
disease, but it is only used in atopic dermatitis. Since hands as an eczema-affected area 
are specificated into a separate body area, the score can as well be used in assessing 
hand eczema.  
 
SCORAD (Scoring Atopic Dermatitis index) 
“SCORAD index consists of the interpretation of the extent of the disorder (A: according 
to the rule of nines; 20% of the score), the intensity composed of six items (B: erythe ma, 
oedema⁄papules, effect of scratching, oozing⁄crust formation, lichenification and 
dryness; 60% of the score; each item has four grades: 0, 1, 2, 3) and subjective 
symptoms (C: itch, sleeplessness; 20% of the score). (15) The rule of nines implies that 
the whole body surface area is divided into areas, which are given 9% each: head and 
neck, each arm, the front and back of each leg and the four trunk quadrants, and 1% for 
the genital area. (16, 17) 
SCORAD is also a widely used scoring system in eczema severity assessment in 
RCTs. It can be used in pediatric dermatology, since it is adaptable to children. Its 
advantage is that, as opposed to SASSAD, it takes subjective symptoms into account, 
apart from the extent and severity of the disease. But due to its extention it is not often 
used in clinical practice.  
 
Photographic guide 
Photographic guide is an instrument of visual assessment of the morphologica l severity 
of CHE. (18) It includes five severity levels: clear, almost clear, moderate, severe, very 
severe; provided with four photographs each, demonstarting various degrees of 
severity of CHE on each stage.  There are photos of both palmar and dorsal views 
presented to complete the picture. Visual assessment is made by physicians. This 
instrument can be used in clinical trials. Though the main limitation of this method is 
that it provides purely visual examination, and does not take into consideration such 
subjective aspects as pruritus or pain and the overall functional impact of disease on the 
patient’s professional and everyday activity . (18) And therefore, solely photographic 
guide cannot do a comprehensive evaluation of disease severity. 
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PGA (Physicians’ Global Assessment) 
PGA severity scale is an instrument used for evaluation of severity of CHE. It consists of 
five degrees of severity: clear, almost clear, mild, moderate, severe; and includes such 
signs and symptoms as erythema, scaling, hyperkeratosis/lichenification, vesiculation, 
oedema, fissures, pruritus/pain. The intensity of each parameter (the description of 
severity is made on a scale from 0 to 3) and the hand area involved are considered 
when defining the degree of severity.(19) The assessment is done by healthcare 
professionals. In the RCT of alitretinoin done by the NICE, PGA was used for assessment 
of CHE. “Severe” PGA score was an eligibility criterion for patients; “almost clear” and 
“clear” were treatment-stopping criterions. (19)  
 
POEM (Patient-Oriented Eczema Measure) 
The POEM is an instrument of assessing atopic eczema in adults and children. This is a 
questionnaire that is filled out by patients themselves basing on their subjective 
perception of their disease. It consists of 7 questions evaluating the disease activity 
during the past week. (20) It includes both symptoms, such as pruritus and sleep 
disturbance, and signs: skin dryness, bleeding, flaking, oozing, cracking. The score is 
given on a scale from 0 to 4, and the maximum score is 28. (20) The advantage of this 
tool is that it provides the evaluation of the disease by the patients according to their 
experience, not by healthcare professionals. It has a form of a short questionnaire, and 
therefore can be used in routine clinical practice.  
 
PBI (Patient Benefit Index) 
PBI is an innovative instrument for evaluation of the treatment benefit. (21) PBI-HE is 
used specifically in the assessment of chronic hand eczema threatment effectiveness. 
The index consists of two questionnaires: the Patient Need Questionnaire and the 
Patient Benefit Questionnaire. “ (1) The ‘Patient Needs Questionnaire’ (PNQ) is filled in 
by the patients before therapy. It contains 27 standardized items on the patient’s needs 
(treatment objectives) such as ‘to no longer experience itching’ and ‘to be able to lead a 
normal everyday life’. Patients rate the importance of each need on a 5-step Likert scale 
ranging from 0 1⁄4 ‘not at all important’ to 4 1⁄4 ‘very important’.  (2) The ‘Patient 
Benefit Questionnaire’ (PBQ) is filled in by the patients during or after therapy. It 
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consists of the same items as the PNQ, but the instruction differs: patients rate the  
extent to which the treatment needs have been fulfilled by therapy on a Likert scale 
ranging from 0 1⁄4 ‘treatment didn’t help at all’ to 4 1⁄4 ‘treatment helped a lot’.“ (21)  
An advantage of this instument is that it makes allowance for patients’ views on 
the needs and benefits of a therapy, as they may differ from those of physicians’. (21) 
Though, since the PBI combines two domains – needs and benefits – the computation of 
a final PBI score is rather complicated: “each importance rating of a treatment need is 
divided by the sum of all importance ratings of a patient to obtain relative importance 
weights. To calculate the PBI, each benefit rating is multiplied by the respective relative 
importance rating and the products are summed. The PBI ranges from 0 (no benefit) to 
4 (maximal benefit).” (21) 
 This method has not yet been widely used, but it was validated in the study of 
efficacy and safety of alitretinoin in CHE (22). (21) 
 
DLQI (Dermatology Life Quality Index) 
The DLQI is the most frequently and internationally used instrument in randomised 
controlled trials in dermatology. A.Y. Finlay and G.K. Khan developed it in 1994. (23) 
The motivation for creating a conceptually new dermatology-specific measure was “a 
need for a simple, compact uniform measure, applicable to patients with any skin 
disease, for use as an assessment tool in routine daily clinical practice .” (23) Now it has 
been used in 33 different dermatoses in 202 studies. (9) 
 “The DLQI is a self-administered, easy and user-friendly questionnaire with an 
average completion time of 126 s. It consists of 10 questions concerning patients’ 
perception of the impact of skin diseases on different aspects o f their QoL over the last 
week.“(9) It has been validated for dermatology patients from the age of 16 and above. 
The items of the DLQI encompass aspects such as symptoms and feelings, daily 
activities, leisure, work or school, personal relationships and the side effects of 
treatment. Each item is scored on a four-point Likert scale: 0, not at all⁄not relevant; 1, 
a little; 2, a lot; and 3, very much. Scores of individual items are added to yield a total 
score (0–30). (9, 23) The higher the scores - the greater the impairment of the patient’s 
QoL. 
 But despite great popularity of the DLQI, there have been some concerns that it 
does not give a full assessment of HRQoL in all skin conditions that it is used in. For 
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instance, it underrepresents some emotional aspects of life of dermatological patients. 
“This might be one of the reasons for unexpectedly low DLQI scores in some patients 
with more emotionally disabling diseases such as vitiligo.” (9) Or, when it comes to 
chronic hand eczema, there also have been some inconsistencies in QoL measurement. 
“Despite the widespread use of the DLQI, it is important to realize that a ‘generic’ 
dermatology-specific QoL measure such as the DLQI may not be sufficient to capture the 
unique constellation of specific skin conditions such as CHE. For example, the number of 
work impairment-related items in the DLQI is underrepresented. Moreover, some items 
may become redundant in CHE, e.g. choice of clothes. This fact is well demonstrated in 
studies of CHE where a score of DLQI even for severe hand disease has been < 10.” (24) 
Therefore, it is recommended to combine the DLQI with a generic instrument, such as 
SF-36, in order to overcome its shortcomings. (9) 
 
Skindex-29/Skindex-17 
The Skindex-29 is a 29-question, three-dimensional, dermatology-specific HRQoL 
instrument, which may well be applied to hand eczema, because it contains questions 
specific to the hands. It consists of 3 main domains: symptoms, emotions, and 
functioning over the past 4 weeks. The domain scores and an overall score are 
expressed on a 100-point scale. A higher score indicates a lower quality of life. (6, 25) 
Obviously the time that it takes to fill out the Skindex-29 questionnaire may be 
significantly longer, than, for instance, DLQI. For that reason there was a shorter version 
of the same questionnaire created – Skindex-17. It consists of 17 items instead of 29, 
and answers are given on a three-point scale instead of a five-point scale. (26) There 
was a study conducted, that investigated whether there were large discrepancies in 
responses to Skindex-29 and Skindex-17. (26) The results of the study showed that “the 
overall correlation was 0.957 for the symptoms scale and 0.940 for the psychosocial 
scale.” (26) Due to a shorter form, and, however, a similar level of precision, specifically 
saving some important phychometric aspects that were mentioned in Skindex-29, 
Skindex-17 may be more frequently used in routine clinical practice. (26) 
 
SF-36 (Short Form – 36) 
“Short Form-36 (SF-36) has been used internationally to assess functional health and 
well being, that is, HRQL, in several long-standing diseases and illnesses. In 
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dermatology, the SF-36 has been used in acne, atopic dermatitis, and psoriasis. Selected 
questions from the SF-36 have also been used in occupational contact dermatitis”. (27)  
The SF-36 is a multi-purpose, short-form health survey with 36 questions, most of 
which cover the health state during the past 4 weeks. It yields an 8-scale profile of 
functional health and well-being scores as well as physical and mental health summary 
measures and a preference-based health utility index. (www.sf-36.org) The 8 domains 
that the questionnaire covers are physical functioning, role limitations due to physical 
problems, bodily pain, general health, vitality, social functioning, role limitations due to 
emotional problems, mental health. (27) 
Since it is a generic measure, it can be used in assessing HRQoL in different 
health conditions enabling comparisons among them. It is possible to use it in the scope 
of dermatology as it includes the aspects of interest for it: limitations of physical 
functioning, social and emotional problems. In dermatology it is used more often than 
another generic instrument – EQ-5D, and it is typically combined with the dermatology-
specific HRQoL measures, like DLQI.  
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3. Effectiveness of the therapies 
Here we will concentrate on the treatment of severe chronic hand eczema. Once hand 
eczema has evolved into chronic (hand eczema of > 6 months’ duration should be  
considered chronic (5)), its prognosis for the patients becomes poor. It is a recurring 
condition with a long-lasting and chronically relapsing course. (2) Individuals suffering 
from CHE refractory to topical corticosteroids have a limited number of treatment 
options with indeterminate effectiveness. For the purposes of this thesis I studied 
several treatment options, including alitretinoin, azathioprine, cyclosporin, 
methotrexate, Grenz (Bucky) rays and UVA/UVB/PUVA irradiation. The information on 
the treatment alternatives is quite limited; it lacks head-to-head trials of the therapies 
and is presented by small-scale RCTs, in most cases, with fewer than 50 patients (see 
Table 1). Therefore I chose azathioprine as the one comparator with the best 
documentation.  
The effectiveness of the treatments presented below is measured by means of 
disease-specific instruments: PGA, SASSAD, SCORAD, and EDI. One study also uses a 
non-formalized scale from 0 to 10. The primary endpoints are “clear”/”almost clear” 
PGA state for alitretinoin, and reduction of disease activity/severity during active 
treatment measured by one of the scales (SASSAD, SCORAD, EDI) for azathioprine. 
 
Alitretinoin 
Alitretinoin is an oral retinoid (9-cis retinoic acid) used in patients with severe CHE 
refractory to topical corticosteroids. This medication has not yet been approved for 
reimbursement in Norway since there is no certainty with respect to its effectiveness. 
There have been no comparative studies of Toctino® versus other systemic treatment 
published.  
The pivotal study of alitretinoin was the largest RCT conducted in the history of 
eczema trials. There were several steps of trials: a 12-week phase II trial (n=319) 
comparing three doses of alitretinoin (10 mg, 20 mg and 40 mg) with placebo; a 24-
week phase III trial (n=1032) comparing daily 10 mg and 30 mg doses with placebo; 
and a trial of extended treatment for those patients who did not respond to alitretinoin 
within the 24-week trial period (n=243). (28, 29) The phase III trial is of most interest 
to this thesis as it included only patients with “severe” chronic hand eczema, whereas 
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the phase II trial included people with both “moderate” and “severe” CHE as defined by 
the PGA score. (29) 
The BACH study (29) was a large (n=1032), randomized, double-blind, placebo-
controlled, multicentre study of up to 24-week duration. The sample was 418, 409 and 
205 adult patients randomized to alitretinoin 10 mg/day, 30 mg/day, and placebo, 
respectively. (2, 22) Refractory status was verified by the following criteria: 
- The patients had received topical corticosteroids for at least 8 weeks (including 
4 weeks of very potent corticosteroids) 6 months before the trial, and had no or 
partial response; 
- They received standard skin therapy (emollients, barrier protection etc.) and 
avoided irritants and allergens without visible improvement; 
- Other conditions mimicing CHE were excluded. (22)  
The exclusion criteria from the trial were:  
- Other dermatological conditions that would interfere with the conduct or 
evaluation of the study; 
- ALT/AST values >250% of the upper limit of normal, tryglycerides > 200% of the 
upper limit, cholesterol >200% of the upper limit and haemoglobin below the 
limit of normal; 
- History of major psychiatric disorders; 
- Other investigational drugs used within the previous 2 months; UVB, PUVA, X-
ray irradiation, systemic corticosteroids, retinoids or immunosupressants within 
the previous 4 weeks; any drugs with potential drug-drug interaction within the 
previous 2 weeks. (22) 
Alitretinoin has a range of adverse events specific to it. It is highly teratogenic, so 
women of child-bearing age participating in the study were required to use at least two 
forms of contraception 1 month prior to, during and 1 month after the trial, and take 
monthly pregnancy tests. (22) The most common side effect was headache, 
mycocutaneous events (dry skin, dry lips, cheilitis), reduced level of thyroid-stimulating 
hormone and increase in total cholesterol and tryglycerids. All adverse events were 
dose-dependent. (22) 
Patients in both alitretinoin groups (10 mg and 30 mg) had a significantly better 
effect than those in the placebo group and responded with “clear”/”almost clear” hands 
as assessed by the PGA. (22) 
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A total of 47.7% (195 of 409 patients; p < 0.001 versus placebo) of alitretinoin 30 
mg/day recipients responded to treatment (22.0% had a ‘clear’ and 25.7% had an 
‘almost clear’ disease area) compared with 16.6% (34 of 205) of placebo recipients 
(2.9% ‘clear’ and 13.7% ‘almost clear’). Alitretinoin 10 mg/day was also significantly (p 
= 0.004) more effective than placebo, with 27.5% (115 of 418) of recipients responding 
(9.3% ‘clear’ and 18.2% ‘almost clear’). (22, 29, 30) 
“Treatment-related adverse events occurred in 34.5%, 37.1% and 49.5% of patients 
on placebo, alitretinoin 10 mg and 30 mg groups, respectively. 1%, 4% and 1% of 
patients withdrew from the alitretinoin 10 mg, 30 mg and placebo groups, respectively, 
due to adverse events.” (30) 
A study of extended therapy with alitretinoin recruited participants of the initial 
alitretinoin trial who did not respond to it. Of the 243 patients enrolled, 53 (21.8%) had 
‘severe’ disease, 136 (56%) had ‘moderate’ disease and 53 (21.8%) had ‘mild’ disease. 
All patients received 30 mg of oral alitretinoin once daily, irrespective of their previous 
treatment regime. (28) Of the patients who had previously received alitretinoin 30 mg, 
alitretinoin 10 mg and placebo, 39.1%, 50.4% and 50.9%, respectively, were rated 
“clear” or “almost clear” by PGA score by the end of this follow-on study. (28) The 
median duration of exposure to alitretinoin 30 mg treatment in the follow-on study was 
168 days. The study showed that alitretinoin 30 mg/day was well tolerated in extended 
treatment as well as during the initial trial. (28) 
The results of the initial study confirm that alitretinoin has a considerable 
therapeutic effect on severe chronic hand eczema refractory to topical corticosteroids. 
(22) 
 
Azathioprine 
Azathioprine is an immunosuppressive medication. There are several RCTs that 
compared its effectiveness with placebo in severe and moderate-to-severe AD.  
 The first trial (31) enrolled 37 participants with severe atopic dermatitis (AD), 
divided into azathioprine group (n=18) and placebo group (n=17). Total duration of the 
trial was 12 weeks with assessments held at week 0, 2,4, 8, and 12. There were 16 
withdrawals from the study (12 versus 4, in azathioprine and placebo group, 
respectively). The primary endpoint was an objective assessment of the disease activity 
from baseline to week 12 by means of SASSAD. The mean SASSAD score at baseline was 
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41 units. At week 12 the mean improvement in the azathioprine group was 10.2 (27%) 
against 0.8 (2%) units in the placebo group (P<0.01). (31) 
 The second trial (32) enrolled 63 patients with moderate-to severe AD, divided 
into azathioprine group (n=42) and placebo group (n=21). The TPMT activity was 
measured in each patient, because the dosage of azathioprine depends on it. Patients 
with low or absent TPMT activity were excluded from the trial due to high risk of 
myelotoxicity. There were 9 withdrawals from the trial (7 versus 2, in azathioprine and 
placebo groups, respectively). The trial duration was 12 weeks with a 12-week follow-
up. The primary endpoint was the mean change in disease activity with SASSAD from 
baseline to week 12. The secondary endpoint combined measurements of itch score, 
body surface affected, QoL (measured with DLQI), global response to the treatment 
assessed by both investigators and participants. At week 12 the mean improvement in 
the azathioprine group was 12.0 (37%) compared to 6.6 (20%) in the placebo group. 
(32) In the secondary endpoint azathioprine also showed significant improvement 
compared to placebo.  (32) 
 The third trial (33) studied 35 patients with severe long-standing AD, resistant to 
conventional therapy. The QoL was measured with EDI; improvement of the patients’ 
eczema after treatment was measured on a scale from 0 (no effect) to 10 (100% 
improvement). The median length of treatment was 7 months (from 1 to 21 months). 
“In the year after azathioprine therapy was stopped, patients received fewer antibiotic 
courses (median, 2; range, -1 to 7), had fewer hospital admissions (median, 1; range, -1 
to 3), fewer outpatient attendances (median, 4; range, -1 to 10), and required fewer 
changes to topical steroids of similar or higher potency (median, 2.5; range, -1 to 7). 
Three patients (8.6%) had little effect from the azathioprine. Eighteen of the 26 patients 
(69.2%) interviewed responded to the azathioprine within 1 month.” (33) Within the 
year after therapy the median difference before and after treatment in EDI score was 22 
(from 6.5 to 32); the mean effect of azathioprine on disease severity on the scale was 
6.9. (33) 
 All three trials demonstrate significant improvement in disease severity with 
azathioprine compared to no treatment.  
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Azathioprine vs. methotrexate 
Both azathioprine and methotrexate are immunosuppressants. There is a trial that 
compared the effectiveness of azathioprine and methotrexate in adults with severe AD. 
(34) It is a single-blind parallel-group RCT (n=42 1:1 ratio). The trial lasted for 12 
weeks with a 12 weeks follow-up. Twenty patients were randomized to methotrexate, 
the other 22 – to azathioprine. The primary endpoint was the mean reduction in eczema 
severity score. At baseline the methotrexate group had a mean SCORAD score of 57.2, 
the azathioprine group – 58. (34) Only antihystamines and topical ointments were 
allowed during treatment as concomitants. Patients, who had undergone phototherapy, 
had been taking any systemic medication or potent topical medication 2 weeks prior to 
the trial, as well as pregnant/nursing women or those planning pregnancy etc. were 
excluded from the study. 
At week 12 of the trial the methotrexate group showed a mean relative reduction 
of SCORAD of 42% (from 57.2 to 34.4), while the azathioprine group - 39% (from 58 to 
36.3). (34) At week 24, the difference between the medications in all outcome 
measurements was reported to be not statistically significant (p=0.58). (34) 
Both azathioprine and methotrexate are effective in treating severe AD, but there 
was no evidence about their efficiency in severe hand eczema of other types.  
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METHODS 
 
1. Literature search 
 
Using the Pubmed database, I conducted two systematic literature reviews, one on 
effectiveness of therapies (RCTs) and one on cost-effectiveness. A systematic review of 
the RCTs was conducted through the PubMed database. The main keywords for the RCT 
search were randomized controlled trial AND eczema. They were in turn combined with 
additional keywords such as hand eczema, severe eczema, placebo, alitretinoin, 
azathioprine, cyclosporine, methotrexate, Grenz rays, UVA UVB, PUVA. Each Pubmed hit 
was scrutinized with respect to title relevance. In case it was relevant, the abstract was 
read. If this was also relevant, the full article was acquired.  Additionally I scrutinized 
the reference lists of the identified articles and obtained PDF files for the relevant 
papers. All the articles used in this thesis are mentioned in the reference list.  
For the search for the previous CEAs of hand eczema therapy the main keywords 
were cost-effectiveness AND hand eczema. They were combined with additional terms 
such as CEA, dermatitis, alitretinoin, cyclosporin, azathioprine, methotrexate, Grenz rays, 
UVA, UVB, and PUVA. There were in total nine hits for all keyword combinations, and 
they were studied with respect to relevance of the titles. Among the nine titles, four 
seemed relevant, but two of them were excluded on the basis of abstract. The remaining 
two papers were read in full and were relevant. The two papers are briefly presented 
below. 
Blank and co-workers (35) assessed the cost-effectiveness of alitretinoin in 
patients with chronic hand eczema from a third party payer perspective in Switzerland. 
A Markov model with two arms, alitretinoin and standard emollient therapy, and a 
time-horizon of 22.4 years was used for the simulation. The costs were measured in 
Euros (€) and the effectiveness in QALYs. At the end of the simulation the long-term 
costs of alitretinoin and emollient therapy were €42,208 and €38,795, respectively, 
while the net QALY gain of alitretinoin was 0.230 QALYs. (35) The estimated ICER was 
consequently €14,814 per QALY, which was deemed cost-effective from the Swiss 
perspective. (35) 
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 A NICE Single Technology appraisal of alitretinoin in CHE (2) encompassed 
economic evaluation of alitretinoin compared to placebo. The study presented 
estimates of the costs and QALYs from the NHS perspective. The authors conclude that 
“in the manufacturer’s original submission to NICE, the base-case ICERs reported for 
alitretinoin were £8,614 per QALY versus ciclosporin, -£469 per QALY versus PUVA 
(with alitretinoin dominant) and £10,612 per QALY versus azathioprine. In the revised 
model, which compared alitretinoin only with placebo, the ICER was estimated at 
£12,931 per QALY.” (2) However, the Evidence Review Group considered the results 
presented by the manufacturer unreliable, because they did not include a probabilistic 
sensitivity analysis. According to the review group, there was considerable uncertainty 
associated with the results of the study, therefore cost-effectiveness of alitretinoin 
cannot be claimed. 
 As long as there is a lack of valid data on the comparative effectiveness of the 
therapy alternatives for hand eczema, it makes it difficult to estimate the cost-
effectiveness of alitretinoin compared to other treatments.  
 
2. Model 
 
To estimate the expected costs and outcomes of alitretinoin and azathioprine for the 
treatment of hand eczema I developed a decision tree model using TreeAge Pro® 2014. 
Though it is not often used for chronic or relapsing diseases, such as chronic hand 
eczema, the short-term time horizon of this model (12 months) makes decision trees 
suitable. (Drummond M. et al., 2005) 
A decision tree has the following structure (Drummond M. et al., 2005): decision 
nodes that represent the decision(s) being addressed in the model; chance nodes that 
indicate uncertain outcomes; branches that represent possible strategies or events that 
a patient can experience; and pathways that are made of branches and that patients 
pass along though the model. The pathways are mutually exclusive (i.e. a patient can 
only follow one) and collectively exhaustive (i.e. they cover all pathways a patient could 
possibly follow). Each event in the decision tree is assigned a certain probability. 
Pathway probabilities must sum to 1, since they are mutually exclusive. The costs and 
outcomes associated with the presented pathways are weighted by the respective 
probabilities in order to calculate the expected values of the treatments.  
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Figure 1. Decision tree model 
 
 
The model has three strategies: alitretinoin 10 mg, alitretinoin 30 mg and azathioprine. 
The two different alitretinoin doses imply different probabilities of cure associated with 
them, different costs and different quality of life. 
The alitretinoin strategies entail the following events: cleared or not within 24 
weeks; relapse or not within 24 weeks after becoming cleared; cleared or not within 12 
weeks after relapse; cleared or not during extended treatment of 48 weeks.  
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The azathioprine strategy first entails a TPMT test (a test for thiopurine 
methyltransferase activity) as long as there is a correlation between the TPMT activity 
and potentially severe adverse events in a patient. (36) People with very low or absent 
TPMT activity taking azathioprine have a high risk of myelotoxicity (32), and should not 
receive this medication. If the test indicates no TPMT activity, a patient receives topical 
corticosteroid 0.1% betamethasone valerate and carbamide cream instead. This 
pathway has the following events: cleared or not during the 24 weeks, and relapse or 
not within 24 weeks after becoming clear. In case of a relapse or not becoming clear 
after 24 weeks patients are assumed to receive only carbamide cream. If the test 
indicates “normal TPMT activity” or “intermediate TPMT activity” , patients receive 
azathioprine treatment and the course of the treatment is modelled as for alitretinoin: 
cleared or not within 24 weeks; relapse or not within 24 weeks after becoming cleared; 
cleared or not within 12 weeks after relapse; cleared or not during extended treatment 
of 48 weeks. Patients with “absent TPMT activity” are assigned to a topical steroid 0.1% 
betamethasone valerate cream and carbamide cream.  
The chosen time perspective of the model is 48 weeks (≈1 year). The initial 
course duration is 24 weeks. After successful treatment patients are followed-up for 24 
weeks with respect to a possible relapse. In case treatment has failed during the first 
24-weeks course, patients receive another 24-weeks course.  
The costs of the treatments are counted from the third-party payer perspective.  
Two types of sensitivity analyses were conducted in this study. I conducted a 
one-way sensitivity analysis by means of a Tornado diagram to describe the uncertainty 
deterministically, as well as a probabilistic sensitivity analysis be means of a Monte 
Carlo simulation with 10,000 samples. Distributions were assigned depending on the 
type of the parameter. Probabilities take values from 0 to 1, and therefore beta 
distribution was assigned to these parameters. Beta distribution is conjugate to 
binomial distribution and is restricted to the interval from 0 to 1. Costs can take values 
from 0 to +∞. Since it cannot take negative values and is not restricted to 1 on the upper 
bound, I assigned gamma distribution to the parameters of costs. Utility parameters, in 
principle, can take any values; negative values can be used in case of a ”worse than 
death” state. Since hand eczema is not a state ”worse than death”, it takes only positive 
values. Since utility parameters in this case are restricted to an interval between 0 and 
1, beta distribution is used. (Briggs A., Sculpher M., Claxton K. Decision Modeling for 
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Health Economic Evaluation, 2006) The mean values for the distributions were taken 
from the deterministic values. The standard deviation from the mean was assumed to 
be 20%. 
 
Dosage 
The treatment dosage was based on the trials (2, 22, 29, 31, 32, 37) and guidelines (36, 
38, 39). The BACH study explored two alitretinoin doses: 10 mg or 30 mg. Indication for 
the choice of the doses was not specified.  
Indication for the choice of azathioprine dose is specified in the RCTs (31, 32) 
and guidelines (36, 38, 39) studying the use of azathioprine in dermatology. The dose in 
the range of 1-3 mg/kg/day is suggested for prescription if a patient has intermediate 
or normal TPMT activity. People with intermediate TPMT activity require a daily dose of 
1.0-1.5 mg/kg, while those with normal TPMT activity require 2.0-3.0 mg/kg/day, 
respectively. (36) For the purposes of this thesis I took the dose regimen from the study 
by Meggitt et al. (32), where patients with intermediate TPMT activity receive 1.0 
mg/kg/day, and patients with normal TPMT activity – 2.5 mg/kg/day. The mean weight 
of an adult in Norway is assumed to be 75 kg.  
 
Costs 
All costs associated with both strategies are listed in Table 1. The drug costs mentioned 
in the model were obtained from the Norwegian “physician desk book” Felleskatalogen 
(www.felleskatalogen.no). The mean cost of oral contraception was calculated from the 
prices of the medications listed under the register code G03A A at Felleskatalogen.  
 Costs of most laboratory tests were obtained from the regulations on 
compensation of expenses for medical care (Forskrift om godtgjørelse av utgifter til 
helsehjelp som utføres poliklinisk ved statlige helseinstitusjoner og ved helseinstitusjoner 
som mottar driftstilskudd fra regionale helseforetak, 2014). The mean cost of urine test is 
assumed to be NOK 5 based on an expert opinion. The cost of a TPMT test was taken 
from the British Association of Dermatologists’ guidelines for the safe and effective 
prescribing of azathioprine 2011 (36), and was converted from English pounds (£) to 
Norwegian kroner (NOK). 
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 All the pregnancy-related costs (cost of oral contraception and pregnancy tests) 
were calculated assuming that the proportions of men and women in the sample 
equaled 50%.  
 The costs of visit to a GP visit (NOK335) and to a private practicing dermatologist 
(NOK514) were based on the Fee Schedule for the Norwegian Medical Association (40) 
and included patients copayments for consultations, fees paid by the health insurance 
system (NAV), annual capitation fees and block grants (driftstilskudd) paid by the 
regional health authority. The cost of a visit to a dermatologist in a hospital (NOK774) 
was based on the Norwegian DRG price list. (41) It was assumed that 50% of the 
physician visits were made to a dermatologist in private practice and 50% to an 
outpatient-clinic. The mean of the two costs was taken as a cost of a dermatologist visit. 
VAT is excluded from the costs of drugs that are used in the model. 
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Table 1. Unit costs and period costs in 2014 Norwegian Kroner (NOK)* 
 
Cost Item  Unit cost  Cost per week  Cost per 24 weeks 
Drugs    
Alitretinoin 10mg/30mg (30 tab) 
(Toctino®, Stiefel, GSK) 
3510.00 819.00 19656.00 
Azathioprine 50mg (100 tab) 
(Imurel® , Aspen Europe GmbH) 
106.425 (2.5mg/kg) – 27.93 
(1.0mg/kg) – 11.18 
(2.5mg/kg) – 670.32 
(1.0mg/kg) – 268.38 
0.1% betamethasone valerate cream 
(Betnov at®  GSK, 100ml) 
64.00 21.00 64.00 
Carbamide cream Canoderm® 5%  
(ACO hud, 500 g) 
359.25 15.00 359.25 
Oral contraception 
(assuming the proportion of women is 
50%) 
70.875 17.70 424.80 
Procedures     
TPMT test 
(AZA) 
300.00 - 300.00 
Pregnancy test  
(assuming the proportion of women is 
50%) 
15.50 - 108.50 
CBC 70.00 - 140.00 
Blood chemistry (Alit) 100.00 - 200.00 
Liver function test (AZA) 60.00 - 120.00 
Iron metabolism (Alit) 50.00 - 100.00 
Thyroid function (Alit) 30.00 - 60.00 
Urine analysis  
(Alit) 
5.00  10.00 
Other    
GP visit  334.75 - 334.75 
Dermatologist visit (private practice) 513.93 - 1541.79 
Dermatologist visit (out -patient clinic) 774.67 - 2324.01 
* Drug costs excluding VAT 
 
Probabilities 
The probabilities of response are based on the data from alitretinoin (22, 28, 37) and 
azathioprine (32) trials. These probabilities are the probabilities of response within 24 
weeks, the probabilities of a relapse within 24 weeks after achieving the “clear/almost 
clear” state, the probabilities of moving back to the “clear/almost clear” state within 24 
weeks after the relapse, and the probabilities of response during extended treatment of 
48 weeks.  
 25 
 The probabilities in alitretinoin strategies, as reported in the trials , are dose-
dependent.  The azathioprine strategies are assumed to have equal probabilities of 
response in 1.0 mg/kg and 2.5 mg/kg dose regimens, because the dose-dependence was 
not reported in the trial.  
 The probabilities of interest for the carbamide branch were also obtained from 
the trials (42-44).  
  
Table 2. Probabilities of treatment response 
Variable Base-case value Range 
Alit10Cl ear24 0.28 0.224-0.336 
Alit10Cl earAfterRelapse 0.48 0.384-0.576 
Alit10ExtTreatClear 0.5 0.4-0.6 
Alit10Relapse24 0.25 0.2-0.3 
Alit30Cl ear24 0.48 0.384-0.576 
Alit30Cl earAfterRelapse 0.8 0.64-0.96 
Alit30ExtTreatClear 0.39 0.312-0.468 
Alit30Relapse24 0.38 0.304-0.456 
AzaCl ear 0.2 0.16-0.24 
AzaCl earAfterRelapse 0.5 0.4-0.6 
AzaExtClear 0.5 0.4-0.6 
AzaRelapse 0.5 0.4-0.6 
CarbamideImp 0.5 0.4-0.6 
CarbamideRelapse 0.32 0.256-0.384 
 
The probabilities of patients having different TPMT activities are obtained from the 
respective studies (45, 46). 
Table 3. Probabilities of different TPMT activity 
Variable Base-case value Range Reference 
Normal TPMT activity 0.887 0.7096-1 (45, 46) 
Intermediate TPMT activity 0.110 0.088-0.132 (45, 46) 
Absent TPMT activity 0.003 0.0024-0.0036 (45, 46) 
 
Health-Related Quality of life 
All the trials used the DLQI instrument to estimate the health-related quality of life 
(HRQoL). Since no direct utility data were collected in the trials, the HRQoL values 
needed to be translated into EQ-5D utility scores. For these purposes I used the 
following formula mentioned in the study by Blank et al: 
EQ-5 D utility score = 0.956 - [0.0248 × (DLQI total score)] (35, 47) 
The formula was extracted from the Health Technology Assessment of psoriasis 
treatment by Woolacott et al (47), p.48. The analysis conducted by Woolacott et al 
estimated “each one-point increase in the DLQI to be associated with a fall of 0.0248 in 
 26 
patient utility.”(47) Blank and coworkers argue that patients with severe psoriasis with 
a DLQI score greater than 10 can be compared with severe chronic hand eczema 
patients with a DLQI score greater than 10 with regard to their impaired quality of life, 
and hence a “mapping” exercise can be conducted in order to estimate the utility 
weights (measured with EQ-5D) from the associated quality of life scores (measured by 
DLQI). (35) 
 The utilities were calculated this way for all the health states in the model.  
Table 4. Utility weights 
Health state EQ-5D weight DLQI score Reference 
Severe  0.625 15.08 (36) 
Moderate 0.761 7.86 (35) 
Clear 0.913 1.74 (35) 
Carbamide (clear) 0.836 4.84 (42) 
Carbamide (relapse) 0.779 7.1 (42) 
 
Cost-effectiveness threshold 
The Directorate of Health issued a guide for the economic evaluation of healthcare 
(Økonomisk evaluering av helsetiltak – en veileder, 2012) in which the statutory cost-
effectiveness threshold was considered to be NOK588,000 (2012-kroner) per life-year 
gained. (48) It estimates the maximum cost the society should be willing to pay for a 
life-year gained with an intervention. This value is used as the WTP in the current 
model. 
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RESULTS 
The base-case results show that a one-year expected QALY was 0.681 for the 
azathioprine strategy, 0.701 for alitretinoin 30 mg and 0.695 for alitretinoin 10 mg, 
while the expected costs were NOK6061 for azathioprine, NOK37,297 for alitretinoin 30 
mg, and NOK40,339 for alitretinoin 10 mg, respectively. The incremental cost-
effectiveness ratio of alitretinoin 30 mg shows that this strategy is not cost-effective, 
since it is way above the proposed cost-effectiveness threshold. The alitretinoin 10 mg 
strategy is dominated since its ICER has taken a negative value. 
 
Table 5. Costs (2014 Norwegian Kroner (NOK)), effectiveness and incremental 
cost-effectiveness (ICER) of three treatments for severe hand eczema 
 
 
Cost Incremental 
cost 
Effectiveness Incremental 
effectiveness 
ICER 
Azathioprine 6061  0.681   
Alitretinoin 30 mg 37297 31236 0.701 0.02 1,561,800 
Alitretinoin 10 mg 40339 3042 0.695 -0.006 dominated 
 
Sensitivity analyses 
The main results are presented in the cost-effectiveness acceptability curve, scatter plot 
and Tornado diagram below. 
 
Figure 2. Cost-effectiveness acceptability curve of the strategies 
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In the CEAC we can see that azathioprine is a cost-effective strategy with the probability 
of more than 74% regardless of the WTP for a QALY.  It indicates that the ICER falls 
below the cost-effectiveness threshold in 100% of the time when the WTP is NOK0, and 
reaches 74.6% while the WTP reaches NOK588,000. Alitretinoin 30 mg is cost-effective 
23.6% of the time with the WTP value of NOK588,000, while alitretinoin 10 mg is cost-
effective 1.8% of the time at the maximum WTP. 
 
 
Figure 3. Joint distribution of cost and outcome from Monte Carlo Simulation in 10,000 
iterations 
 
 
From the scatterplot we can see that azathioprine demontrates higher effectiveness at a 
much lower cost than both alitretinoin strategies. With 10,000 iterations the 
effectiveness values of azathioprine fall between 0.53 and 0.79 QALYs with the 
approximate cost of NOK6000. Distributions of alitretinoin 10 mg and 30 mg are 
represented by two overlapping clouds, but it is still possible to define that both 
strategies demonstrate approximately equal effectiveness, with alitretinoin 10 mg 
requiring higher costs, up to NOK53000. 
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The deterministic sensitivity analysis was conducted in order to get more insight into 
the importance of uncertainty in the individual parameters. I constructed a Tornado 
diagram to check which parameters had the greatest impact on the results. Lacking 
empirical data on uncertainty of the parameter values, I assumed a range of +/- 20% of 
the base case value for each parameter. The diagram shows that the QoL at “severe” 
state in the azathioprine strategy, QoL at “moderate” state in azathioprine, QoL of 
“clear” state, QoL in “moderate” state in alitretinoin, and QoL in “severe” state in 
alitretinoin strategy are the parameters that have the greatest impact on the result. 
Even taking this uncertainty into consideration, however, azathioprine is more cost-
effective than the other strategies. For instance, with the QoL value of the “severe” state 
in the azathioprine strategy at the lowest bound of 0.5752, the ICER would be 388,784 
NOK/QALY, while at the upper bound of 0.8628 the ICER would be 445,878 NOK/QALY.  
 
 
Figure 4. Tornado diagram (deterministic sensitivity analysis)  
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Table 6. One-way sensitivity analysis of the parameters that were the most 
important according to the Tornado analysis  
  ICER (lower-upper) ICER (lower-upper) ICER (lower-
upper) 
Parameter Base case 
(range) 
Alitretinoin 10 mg Alitretinoin 30 mg Azathioprine 
qAzaModerateSevere 0.625  
(0.5752-0.8628) 
(dominated/ dominated) (1,030,151/ dominated) NA 
qAzaModerate 0.761  
(0.6088-0.9132) 
(dominated /dominated) (448,028/ dominated) NA 
qAlitClear 0.913  
(0.7304-1.0) 
(944,228/dominated) (ext.dominated/ 
1,648,835) 
NA 
qAlitModerate 0.761  
(0.6088-0.9132) 
(dominated/ 1,027,516) (dominated/ 493,545) NA 
qAlitSevere 0.625  
(0.5-0.75) 
(dominated/dominated) (dominated/514,405) NA 
  
 31 
Discussion 
 
The results of this study indicate that the azathioprine strategy dominates alitretinoin 
10mg and is more cost-effective than alitretinoin 30mg strategy, since azathioprine 
entails lower costs and similar health outcomes. The results, however, should be 
considered against the methodological limitations of the study.  
 
Strengths of the study 
In this thesis I conducted a literature search and a systematic review of the RCTs and 
cost-effectiveness analyses. As far as I had decided upon the two comparators for my 
analysis (alitretinoin and azathioprine), I excluded all the articles studying other 
treatment alternatives from the thesis (cyclosporin, methotrexate, Bucky rays, UV -
irradiation), however, the overview of the treatments’ effectiveness is presented in the 
Appendix. This study adds to the current literature in that it compares alitretinoin to 
active treatments while published economic evaluation of alitretinoin have used 
placebo as the comparator. 
 
Limitations of the study 
There were several assumptions made in the thesis either due to the lack of data or in 
order to simplify the model. 
Chronic hand eczema is a recurrent condition, and under ideal conditions the 
time horizon of the model should be a life time or at least several years. However, the 
lack of data on the long-term effectiveness of the drugs may justify a shorter time 
perspective.  
One of the drugs, azathioprine, is used only in treatment of atopic eczema, while 
alitretinoin may, in principle, be used for treating any type of chronic eczema. 
The trial data for effectiveness stems from the UK and other European countries. 
However, the effectiveness of the two drugs is likely to be the same across countries. 
The model was developed according to the reporting of the RCTs, but the model 
was not validated by a dermatologist. Some of the parameters, such as number of 
dermatologist visits, amount of carbamide cream used, amount of steroids used, 
number of lab tests conducted etc., may need to be adapted to reflect real life practice. 
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For simplicity purposes it was assumed that a relapse after being “cleared” 
happens at week 36 in all the strategies, and eczema gets “cleared” or “not cleared” until 
the end of the time horizon of 48 weeks, i.e. within 12 weeks.  
Dosage 
 Azathioprine is assumed to be given to patients in full dose (1.0 mg and 2.5 mg) 
from the onset of the treatment. Meggitt and coworkers (32) reported that the doses 
were reduced from 1.0 mg and 2.5 mg to 0.5 mg and 1.0 mg, respectively, for the first 4 
weeks of the treatment in order to avoid adverse events. This could be a precaution 
measure for the purposes of the trial, and I did not follow this dose regimen in this 
thesis. 
 The different doses of azathioprine for patients with intermediate and normal 
TPMT activity, 1.0 mg and 2.5 mg, respectively, are assumed to be equally effective. 
Since the TPMT activity is lower, the lower dose of azathioprine is considered to be as 
effective as of the normal dose. 
Probabilities  
Assumptions referring to the probabilities had to be made in the azathioprine strategy 
due to the lack of trial data or a qualified expert panel. The probabilities of a relapse, 
becoming clear after the relapse, becoming clear after extended treatment, and 
becoming clear with corticosteroids and carbamide treatment were not available from 
the trials, and therefore were assumed to be 50%. I assumed they should be equal in 
order to avoid making any inferences about the possible outcome. 
Lacking an expert panel on the TPMT test specificity and sensitivity, it is 
assumed to be perfect.  
Health Related Quality of Life 
Primarily different instruments for measurement of effectiveness are used in the 
alitretinoin and azathioprine studies. PGA is used in the alitretinoin study, while 
SASSAD is used in the azathioprine study. These instruments might not be fully 
consistent with each other. 
The utilities in the model are measured only basing on the HRQoL of the health 
states and their duration. Adverse events from the treatments are assumed not to have 
any influence on the QoL. 
I assumed that for the purposes of consistency the QoL in which the patients 
enter the model and which they end up after becoming clear should be the same in all 
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the strategies. In the azathioprine trial that had been used, patients are in a moderate -
to-severe state at the onset of the treatment, and, hence, have higher utilities and higher 
clearance rate. The probabilities of becoming clear with azathioprine of either dosage 
were reduced from 0.39 claimed in the trial, to 0.20. The respective utilities were 
reduced to those in the alitretinoin branches. 
The effectiveness of carbamide treatment is adjusted to the PGA “severe” state. 
The patients entered the trials in the mild-to-moderate state, and hence the QoL scores 
before and after treatment, that were claimed in the trials (42, 44), are high. These 
utility weights were unsuitable for the patients in “severe” state. Therefore, I assumed 
the QoL at the onset of treatment to be 0.625 (“severe” state, since all patients are 
assumed to start with this QoL), the QoL of the moderate state – 0.761, the QoL after 
some improvement of eczema – 0.771 (patients at relapse after treatment with 
carbamide cream (42)), and the QoL of the “cleared” state - 0.836 (patients at inclusion 
of the carbamide treatment (42)). It is assumed that the patients from the carbamide 
branch never reach the “clear” state with the utility of 0.913. 
Costs  
For purposes of simplicity I assumed that the proportions of men and women in 
the samples are equal and make 50%. Hence, all the costs associated with pregnancy 
prevention were halved.  The proportions of patients visiting a privately practicing 
dermatologist and a dermatologist at an outpatient clinic are also assumed to be 50%, 
and a mean cost of a dermatologist visit was calculated accordingly. 
The cost of a TPMT test was taken from the British guidelines for prescribing 
azathioprine in dermatology (36) since the Norwegian cost was not available. The costs 
are assumed to correlate with each other. 
  
Comparison with other studies 
To the best of my knowledge, no other cost-effectiveness studies of alitretinoin against 
active comparators have been published. The two CEAs mentioned in the Methods 
section explored its cost-effectiveness compared to placebo.  
Rodgers et al (2) evaluated a cost-effectiveness analysis of alitretinoin against 
placebo conducted by the manufacturer (Basilea Pharmaceuticals Ltd, Basel, 
Switzerland) for NICE. Rodgers concluded that the cost-effectiveness claimed by the 
manufacturer, is highly uncertain. “The base case ICERs of alitretinoin reported for 
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alitretinoin were £8614 per QALY versus ciclosporin, -£469 per QALY versus PUVA 
(with alitretinoin dominant) and £10,612 per QALY versus azathioprine (year 2007–8 
values).”(2) The revised analysis with placebo as a comparator indicated an ICER of 
£12,931 per QALY.  
There were several points of uncertainty of the result. Firstly, no probabilistic 
sensitivity analysis was conducted. Secondly, adverse events associated with the 
treatments were omitted from the analysis. The CEA performed by the NICE was based 
on HRQoL reductions that accounted for side effects. This revision doubled the ICER, 
that reached £30 000 per QALY. (2) Due to a high degree of uncertainty about the ICER, 
NICE concluded that alitretinoin is not considered cost-effective for use in the NHS.  
Blank et al (36) conducted a CEA of alitretinoin comparing it to standard 
emollient treatment from the Swiss third party payer perspective. Carbamide cream 
was probably used in the comparator arm, but since it is not specified in the trial, 
standard emollient therapy can be considered a placebo. They developed a Markov 
model with a cycle length of 1 year and a time perspective of 22.4 years. The base case 
total costs of treatment with alitretinoin and emollients were estimated at €42,208 and 
€38,795, respectively. The mean QALY in the alitretinoin group was 11.21 QALYs, while 
in the comparator group it was 10.98 QALYs, implying an ICER of €14,816 per QALY.  
Alitretinoin was considered cost-effective from the Swiss perspective.  
There are several uncertainties associated with this study. Firstly, they did not 
use an active treatment as a comparator, which may have influenced the final result. 
Secondly, they did not run a probabilistic sensitivity analysis, only several one-way 
sensitivity analyses, so the overall decision uncertainty was not evaluated.  
The results of my study are consistent with the CEA run by NICE, which indicated 
that alitretinoin is not cost-effective. The study by Blank and coworkers had different 
results due to the difference in the study design and input data.  
 
Implications 
The results of this study indicate that alitretinoin is either dominated (10mg) or has an 
ICER beyond what is usually accepted for the Norwegian health care system (30mg). 
The Norwegian Directorate of Health has suggested a threshold of NOK588,000 per 
QALY, and the ICER for alitretinoin 30 mg is beyond that amount (48). Based on these 
results, alitretinoin should not be publicly funded at the current price. If the price of 
 35 
alitretinoin were reduced to NOK1847 (excluding VAT), it would be considered cost-
effective with the ICER of NOK588,000 per QALY. 
 
Conclusion 
The study indicates that under current conditions alitretinoin is not a cost-effective 
treatment of chronic hand eczema. There is, however, considerable uncertainty 
associated with the results of this study. Due to the lack of trial data or an expert panel, 
assumptions had to be made which may influence the conclusive result of the cost-
effectiveness analysis. We need additional information on the clinical effectiveness of 
alitretinoin compared to other active treatments in order to make decisions about its 
cost-effectiveness.  
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Appendix 
1. DLQI questionnaire 
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2. PGA severity score 
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3.  POEM questionnaire 
 
 
4. HECSI 
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5. SASSAD 
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